Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

Blood (2024) 144 (Supplement 1): 4535.

https://doi.org/10.1182/blood-2024-202477

Published: 2024

Journal Articles

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 - 60 Years: A “Campus CML” Study

Blood (2024) 144 (Supplement 1): 1772.

https://doi.org/10.1182/blood-2024-207175

Published: 2024

Journal Articles

CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

Blood (2024) 144 (Supplement 1): 3155.

https://doi.org/10.1182/blood-2024-207877

Published: 2024

Journal Articles

The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

Blood (2023) 142 (Supplement 1): 3168.

https://doi.org/10.1182/blood-2023-182981

Published: 2023

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase Showing Clinical Resistance to Frontline Treatment with Second Generation Tyrosine Kinase Inhibitors. an Italian Prospective Study from the CML Campus

Blood (2023) 142 (Supplement 1): 6363.

https://doi.org/10.1182/blood-2023-188523

Published: 2023

Journal Articles

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Blood (2022) 140 (Supplement 1): 3920–3922.

https://doi.org/10.1182/blood-2022-164790

Published: 2022

Journal Articles

Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study

Blood (2022) 140 (Supplement 1): 3906–3907.

https://doi.org/10.1182/blood-2022-170415

Published: 2022

Journal Articles

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

Blood (2021) 138 (Supplement 1): 1487.

https://doi.org/10.1182/blood-2021-149780

Published: 2021

Journal Articles

Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141077

Published: 2020

Journal Articles

Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study

Giorgina Specchia, MD, Patrizia Pregno, Massimo Breccia, MD, Chiara Monagheddu, Fausto Castagnetti, MDPhD, Massimiliano Bonifacio, MD, Mario Tiribelli, MD, Fabio Stagno, MD PhD, Giovanni Caocci, MD, Bruno Martino, MD, Luigiana Luciano, MD, Michele Pizzuti, MD, Antonella Gozzini, MD, Anna Rita Scortechini, MD, Francesco Albano, Micaela Bergamaschi, MD, Isabella Capodanno, MD, Andrea Patriarca, MD, Carmen Fava, Giovanna Rege Cambrin, MDPhD, Federica Sorà, MD, Sara Galimberti, MD PhD, Monica Bocchia, Gianni Binotto, MD, Giovanni Reddiconto, Attilio Guarini, MD, Alessandro Maggi, Grazia Sanpaolo, MD, Maria Stella De Candia, Valentina Giai, MD PhD, Elisabetta Abruzzese, MD, Maria Cristina Miggiano, MD, Franca Falzetti, MD, Gaetano La Barba, Giuseppe Pietrantuono, Anna Guella, MD, Luciano Levato, MD, Olga Mulas, Fabio Saccona, Gianantonio Rosti, MD, Pellegrino Musto, MD, Francesco Di Raimondo, MD, Fabrizio Pane, MD, Robin Foà, MD, Michele Baccarani, MD, Giovannino Ciccone, Giuseppe Saglio, MD PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-139307

Published: 2020

Journal Articles

Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group

Blood (2018) 132 (Supplement 1): 45.

https://doi.org/10.1182/blood-2018-99-116648

Published: 2018

Journal Articles

Efficacy and Safety of Bendamustine and Rituximab As First Salvage Treatment in Chronic Lymphocytic Leukemia: Results of the Gimema-Eric LLC1315 Study

Blood (2017) 130 (Supplement 1): 4330.

https://doi.org/10.1182/blood.V130.Suppl_1.4330.4330

Published: 2017

Journal Articles

A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy in CML Patients

Luigia Luciano, MD, Giorgina Specchia, MD, Bruno Martino, Vincenzo Accurso, MD, Marco Santoro, MD, Alessandra Malato, MD, Nicola Sgherza, Michele Pizzuti, MD, Fabio Stagno, MD PhD, Pellegrino Musto, MD, Attilio Guarini, MD, Fiorenza De Gregorio, MD, Santina Basile, MD, Fabrizio Pane, MD

Blood (2017) 130 (Supplement 1): 2905.

https://doi.org/10.1182/blood.V130.Suppl_1.2905.2905

Published: 2017

Journal Articles

Association Between Immunoparesis and a Skewed Free Light Chain (FLC) Ratio: A New Prognostic Factor Of Progression from MGUS To Multiple Myeloma?

Michele Pizzuti, Alberto Santagostino, Giuseppina Smaldore, Ida Chitarrelli, Domenico Vertone, Sara Pasquina Pascale, Angela Matturro, Immacolata Attolico, Angela Amendola, Michele Cimminiello, Nunzio Filardi, Antonella Girardi, Romina Penitente, Roberta Nuccorini, Sabrina Coluzzi, Enza Scavone

Blood (2013) 122 (21): 5314.

https://doi.org/10.1182/blood.V122.21.5314.5314

Published: 2013

Journal Articles

Evaluation Of Factor V Leiden, Prothrombin Mutations and The Homozygous mutation 677T In The MTHFR Gene In Patients With Venous Thrombosis

Michele Pizzuti, Alberto Santagostino, Maria Antonietta Rizzo, Daniela Dragonetti, Maria Grazia Pietrafesa, Immacolata Attolico, Angela Amendola, Nunzio Filardi, Michele Cimminiello, Angela Matturro, Domenico Vertone, Roberta Nuccorini, sara Pasquina Pascale, Sabrina Coluzzi

Blood (2013) 122 (21): 4798.

https://doi.org/10.1182/blood.V122.21.4798.4798

Published: 2013

Journal Articles

Impact Of Bone Marrow Involvement On Outcome Of Young Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL) Treated In The Phase III Randomized Trial (DLCL04) With Rituximab Dose-Dense Chemotherapy Followed By Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Or Standard Rituximab Dose Dense Chemotherapy: A Study of The Fondazione Italiana Linfomi (FIL)

Blood (2013) 122 (21): 4340.

https://doi.org/10.1182/blood.V122.21.4340.4340

Published: 2013

Journal Articles

Evaluation of MRD Status by Flow Cytometry and PCR in Multiple Myeloma Elderly Patients Receiving Autologous Stem Cell Transplantation After Bortezomib-Supplemented Mobilization and Conditioning

Immacolata Attolico, Roberta Nuccorini, Alberto Fragasso, Vincenzo Pavone, Pellegrino Musto, Silvana Capalbo, MD, Gaetano Palumbo, MD, Giorgina Specchia, Cristiana Carniti, PhD, Paolo Corradini, MD, Sara Pascale, Sabrina Coluzzi, Michele Pizzuti, Angela Amendola, Michele Cimminiello, Angela Matturro, Domenico Vertone, Nunzio Filardi, Attilio Olivieri, MD

Blood (2012) 120 (21): 4523.

https://doi.org/10.1182/blood.V120.21.4523.4523

Published: 2012

Journal Articles

ADAMTS13 Activity and Autoantibodies Subclasses as Recurrency Risk Predictors In Acquired Thrombotic Thrombocytopenic Purpura

Giuseppe Bettoni, Luca A Lotta, Dario Consonni, Dino FA Motti, Roberta Palla, Carla Valsecchi, Gloria Casoli, Andrea Rovati, Michele Pizzuti, Flora Peyvandi, MD, PhD

Blood (2010) 116 (21): 2532.

https://doi.org/10.1182/blood.V116.21.2532.2532

Published: 2010

Journal Articles

Late Onset of Secondary AML with 5q- in CLL with 13q- Abnormality; Coexistence of the Two Neoplastic Clones and the Therapeutic Potential of Lenalidomide.

Imma Attolico, Giancarlo Discepoli, Roberta Nuccorini, Sara Pascale, Sabrina Coluzzi, Michele Pizzuti, Angela Amendola, Attilio Olivieri

Blood (2009) 114 (22): 4394.

https://doi.org/10.1182/blood.V114.22.4394.4394

Published: 2009

Journal Articles

In Vivo Purging Followed by AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) in PATIENTS with MULTIPLE MYELOMA (MM): Preliminary RESULTS of a Pilot STUDY

Imma Attolico, MD, Domenico Vertone, MD, Nunzio Filardi, MD, Michele Pizzuti, MD, Monica Poggiaspalla, MD, Michele Cimminiello, MD, Sabrina Coluzzi, Attilio Olivieri, MD

Blood (2008) 112 (11): 4458.

https://doi.org/10.1182/blood.V112.11.4458.4458

Published: 2008

NARROW

Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 - 60 Years: A “Campus CML” Study

CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase Showing Clinical Resistance to Frontline Treatment with Second Generation Tyrosine Kinase Inhibitors. an Italian Prospective Study from the CML Campus

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study

Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study

Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group

Efficacy and Safety of Bendamustine and Rituximab As First Salvage Treatment in Chronic Lymphocytic Leukemia: Results of the Gimema-Eric LLC1315 Study

A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy in CML Patients

Association Between Immunoparesis and a Skewed Free Light Chain (FLC) Ratio: A New Prognostic Factor Of Progression from MGUS To Multiple Myeloma?

Evaluation Of Factor V Leiden, Prothrombin Mutations and The Homozygous mutation 677T In The MTHFR Gene In Patients With Venous Thrombosis

Evaluation of MRD Status by Flow Cytometry and PCR in Multiple Myeloma Elderly Patients Receiving Autologous Stem Cell Transplantation After Bortezomib-Supplemented Mobilization and Conditioning

ADAMTS13 Activity and Autoantibodies Subclasses as Recurrency Risk Predictors In Acquired Thrombotic Thrombocytopenic Purpura

Late Onset of Secondary AML with 5q- in CLL with 13q- Abnormality; Coexistence of the Two Neoplastic Clones and the Therapeutic Potential of Lenalidomide.

In Vivo Purging Followed by AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) in PATIENTS with MULTIPLE MYELOMA (MM): Preliminary RESULTS of a Pilot STUDY

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only